For interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.     TREAT FAST WITH LUZU   (luliconazole) Cream, 1%   2-week dosing. Efficacy demonstrated at 4 weeks post-treatment.1   NOW ELIGIBLE PATIENTS PAY $0* THROUGH THE END OF THE YEAR       The only topical azole with once-daily, 2-week dosing1         TINEA PEDIS DOSING             The only topical Rx antifungal with once-daily, 1-week dosing1       TINEA CRURIS/CORPORIS DOSING         LUZU (luliconazole) Cream, 1% is an azole antifungal indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.   LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use.               Indications and Usage   LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum in patients 18 years of age and older.   Important Safety Information   LUZU is indicated for topical use only and is not indicated for ophthalmic, oral or intravaginal use.   LUZU should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when LUZU is prescribed for nursing mothers.   The most common adverse reactions in clinical trials were application site reactions, which occurred in less than 1% of subjects in both LUZU and vehicle arms. Most adverse reactions were mild in severity.     * Offer only applies to patients with commercial insurance. Commercially insured patients whose insurance does not cover LUZU may pay more. Cash-paying patients are not eligible. Not valid for patients reimbursed, in whole or in part, by federal health care programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq., or any other similar federal or state health care program. Void where prohibited by law, taxed, or restricted. Void outside the United States.   Patients with questions should call 855-264-0299.   Valeant Pharmaceuticals reserves the right to rescind, revoke, or amend this offer at any time.   Click here for Prescribing Information or visit LUZURX.com.   Reference: 1. LUZU [prescribing information]. Bridgewater, NJ: Medicis, a division of Valeant Pharmaceuticals; 2014.   You have the right to opt out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 30 days of receipt. Please be sure to indicate the e-mail address to which your request relates and reason for opt-out.   Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.         © 2014 Valeant Pharmaceuticals North America LLC DM/LUZ/14/0092